On March 21, 2018 Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, reported that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 3:30 p.m. EST in New York (Press release, Vaxart, MAR 21, 2018, View Source [SID1234524921]). gary2

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation..

On March 21, 2018 Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, reported that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 3:30 p.m. EST in New York (Press release, Vaxart, MAR 21, 2018, View Source [SID1234524921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.

On March 21, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview at the 2018 Needham & Company 17TH Annual Healthcare Conference, being held in New York City on March 27-28, 2018 (Press release, Leap Therapeutics, MAR 21, 2018, View Source;p=RssLanding&cat=news&id=2339079 [SID1234524920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Needham & Company 17TH Annual Healthcare Conference – Leap Presentation Details:
Date: Wednesday, March 28, 2018
Time: 12:15 P.M.

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited time.

On March 21, 2018 Geron Corporation (Nasdaq:GERN) reported that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the 17th Annual Needham Healthcare Conference in New York at 4:00 p.m. Eastern Time on Tuesday, March 27, 2018 (Press release, Geron, MAR 21, 2018, View Source;p=RssLanding&cat=news&id=2339096 [SID1234524919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at View Source Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

On March 21, 2018 Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) reported its financial results for 2017 on Wednesday, 28 March 2018 (Press release, Evotec, MAR 21, 2018, View Source [SID1234524918]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English.

Conference call details

Date: Wednesday, 28 March 2018
Time: 02.00 pm CEST (01.00 pm BST/08.00 am EDT)

From Germany: +49 69 22 22 29 043
From France: +33 170 750 705
From Italy: +39 02 3601 3806
From UK: +44 20 3009 2452
From USA: +1 855 402 7766
Access Code: 37969784#

A simultaneous slide presentation for participants dialling in via phone is available at http://www.audio-webcast.com/, password: evotec0318.